Related by context. All words. (Click for frequent words.) 71 liver metastases 71 metastatic lesions 70 renal tumors 69 pancreatic adenocarcinoma 69 pCR 69 renal cell carcinomas 68 cytoreduction 68 pulmonary metastases 68 metastatic tumors 68 underwent resection 68 ovarian carcinoma 68 cytoreductive surgery 67 histologically 67 hepatocellular carcinomas 67 locoregional disease 67 metastatic lung cancer 67 prostate carcinoma 67 peritoneal carcinomatosis 67 metastases 67 breast carcinomas 67 lymph node metastases 67 pancreatic carcinoma 67 concurrent chemoradiation 67 biochemical relapse 67 colorectal carcinoma 67 metastatic RCC 66 benign nodules 66 locoregional recurrence 66 cervical lymph nodes 66 epithelial tumors 66 preoperative chemotherapy 66 hepatic metastases 66 adrenalectomy 66 liver resection 66 KRAS mutations occur 66 chemoembolization 66 complete cytogenetic response 66 underwent surgical resection 65 lymphocytosis 65 recurrent glioblastoma multiforme 65 radiochemotherapy 65 atypical hyperplasia 65 colorectal liver metastases 65 FOLFOX4 65 advanced adenoma 65 syngeneic 65 nodal metastases 65 graft dysfunction 65 thoracoscopic lobectomy 65 paroxysmal AF 65 postoperative chemotherapy 65 nutlin 3a 65 orthotopic 65 radical nephrectomy 65 NMIBC 65 distant metastases 65 nonsmall cell lung cancer 65 GISTs 65 advanced adenomas 65 nephrectomy 65 hepatectomy 65 superficial bladder cancer 65 squamous histology 65 cell carcinomas 65 Tumor shrinkage 65 histopathologic examination 65 leukemia AML 65 relapsed MM 65 nodal metastasis 65 mutated KRAS 65 glioblastoma tumors 65 squamous cell carcinoma SCC 65 tumor resection 65 octreotide LAR 65 differentiated thyroid 65 ascites 65 atherosclerotic lesions 65 liver metastasis 65 infarct size 65 contralateral breast 65 tumor recurrence 65 FDG uptake 64 basal cell carcinoma BCC 64 skeletal metastases 64 mediastinal lymph nodes 64 ALND 64 patients evaluable 64 melanoma tumors 64 operable breast cancer 64 locoregional 64 5FU 64 lung nodules 64 metastatic melanomas 64 biliary tract cancer 64 mediastinal 64 sonographically 64 rosuvastatin #mg 64 gadolinium enhanced 64 bleomycin 64 unresectable 64 PSADT 64 axillary lymph nodes 64 breast carcinoma 64 adenocarcinomas 64 telomerase inhibition 64 calculi 64 chemoradiation 64 anterior uveitis 64 ischemic lesions 64 brain metastases 64 cisplatin resistant 64 systolic dysfunction 64 colorectal adenoma 64 transurethral resection 64 distant metastasis 64 placebo dexamethasone 64 thymoma 64 chemoradiation therapy 64 TACE 64 stage IIIb IV 64 tumors 63 bladder tumors 63 fallopian tube carcinoma 63 paricalcitol 63 pancreatectomy 63 myocytes 63 nondiabetic patients 63 Mitomycin C 63 CR nPR 63 pulmonary metastasis 63 papillary renal cell carcinoma 63 trabeculectomy 63 recurrent NSCLC 63 Doxil ® 63 glycated hemoglobin levels 63 chlorambucil 63 K ras mutations 63 colorectal adenocarcinoma 63 osteosarcomas 63 immunohistochemical staining 63 unresectable tumors 63 perioperative complications 63 adenomatous 63 tumor regression 63 micrometastases 63 Adjuvant chemotherapy 63 SUVmax 63 hA# 63 mucinous 63 serous ovarian cancer 63 metastatic renal cell carcinoma 63 carcinomas 63 supratentorial 63 postoperative morbidity 63 cytogenetic responses 63 prostate cancer CaP 63 sentinel lymph nodes 63 precursor lesions 63 intraductal 63 tumor shrinkage 63 adjuvant radiation 63 retroperitoneal 63 brain lesions 63 Immunohistochemical analysis 63 neoplastic cells 63 baseline LDH 63 PCa 63 varices 63 pneumonectomy 63 schwannomas 63 chemoradiotherapy 63 fibrin deposition 63 extracapsular extension 63 debulking surgery 63 adenoma 63 follicular lymphomas 63 oblimersen 63 hepatorenal syndrome 63 heavily pretreated 63 estramustine 63 CCyR 63 nonmetastatic 63 HER2 amplification 63 pegylated liposomal doxorubicin 63 mg kg dose 63 repigmentation 63 resected 63 gemcitabine cisplatin 63 osteoporotic vertebral compression fractures 63 basal cell nevus syndrome 63 GIST tumors 63 metastatic prostate cancer 63 nonischemic 63 stage IIIB 63 metastatic neuroendocrine tumors 63 untreated metastatic melanoma 63 hamartomas 63 ductal breast cancer 63 endoscopically 63 partial nephrectomy 63 splenectomized patients 63 intravesical therapy 62 #F FDG 62 epithelial ovarian 62 decitabine 62 biochemical recurrence 62 HSCT 62 intestinal metaplasia 62 metastatic lesion 62 KRAS mutant tumors 62 rebleeding 62 lobular 62 neoadjuvant therapy 62 resectable 62 OPCAB 62 lymph node involvement 62 cystic lesions 62 mitomycin C 62 neoadjuvant chemotherapy 62 axillary dissection 62 serum phosphate levels 62 cystectomy 62 Papillary 62 perioperatively 62 breast cancer subtypes 62 mesotheliomas 62 complete remissions 62 axillary nodes 62 endometrial carcinoma 62 gemcitabine carboplatin 62 colorectal carcinomas 62 hepatocellular carcinoma HCC 62 adjuvant radiotherapy 62 cellularity 62 trans retinoic acid 62 cisplatin chemotherapy 62 relapsed SCLC 62 Gleevec resistant 62 azacytidine 62 gastric adenocarcinoma 62 micrometastasis 62 metastatic gastric 62 normal karyotype 62 mCRC patients 62 thrombi 62 sarcomatoid 62 metastatic lymph nodes 62 histologically confirmed 62 recurrent GBM 62 lung tumors 62 external beam radiotherapy 62 radical cystectomy 62 glomerular filtration 62 Endometrial 62 immunized mice 62 TRUS biopsy 62 mutated K ras 62 metastatic disease 62 completely resected 62 mTOR inhibitors 62 GBM tumors 62 antitumor effect 62 ximelagatran 62 RAS mutations 62 hepatoma 62 Thal Dex 62 thyroid carcinoma 62 Bezielle 62 urothelial cancer 62 pamidronate 62 sentinel node 62 INCB# [003] 62 hemodialysis patients 62 partial remissions 62 Ceplene/IL-2 62 malignant pleural mesothelioma 62 grade gliomas 62 mCi 62 PSA nadir 62 wedge resection 62 CYT# potent vascular disrupting 62 endometrial hyperplasia 62 colon carcinoma 62 tumoral 62 atheroma volume 62 tumor xenograft models 62 prostate adenocarcinoma 62 BRAF mutation 62 esophageal carcinoma 62 liver histology 62 parathyroidectomy 62 myocardial necrosis 62 NNRTI resistance 62 systemic ALCL 62 malignant lesions 62 immunocompetent 62 colorectal polyp 62 colectomy 62 daunorubicin 62 adriamycin 62 metastatic pancreatic 62 neuroblastoma cells 62 thrombocytopenic patients 62 resected pancreatic cancer 62 prostate carcinomas 62 perfusion defects 62 xenograft models 62 CLL cells 62 TIMP 62 mg/m2 dose 62 parathyroid carcinoma 62 CIMZIA ™ 62 B7 H3 62 HGPIN 62 etoposide 62 colorectal tumor 62 intracavitary 62 invasive carcinomas 62 intrahepatic 62 metastatic colorectal 61 bladder cancers 61 infarcts 61 metastatic GIST 61 liver transplant recipients 61 intracranial hemorrhage ICH 61 gastrectomy 61 photocoagulation 61 adjuvant tamoxifen 61 neoadjuvant radiation 61 IV NSCLC 61 prostate cancer PCa 61 autologous SCT 61 Kaplan Meier analysis 61 IFN beta 61 leiomyomas 61 Liver biopsies 61 intraoperative complications 61 hyperintense lesions 61 lung adenocarcinomas 61 ductal adenocarcinoma 61 evaluable patients 61 neovascular 61 hypoperfusion 61 perioperative morbidity 61 heavily pretreated patients 61 peritoneal cancer 61 binary restenosis 61 HER2 positive tumors 61 malignant neoplasm 61 colorectal cancer liver metastases 61 metastatic bladder 61 MGd 61 thymectomy 61 undergone radical prostatectomy 61 TAXUS Express Stent 61 cranial irradiation 61 HBeAg seroconversion 61 metachronous 61 lung metastasis 61 sorafenib Nexavar ® 61 seminal vesicle invasion 61 hypervascular 61 eosinophil count 61 TIMP 1 61 small lymphocytic lymphoma 61 colorectal tumors 61 docetaxel chemotherapy 61 complete cytogenetic 61 intact parathyroid hormone 61 grade cervical intraepithelial 61 R0 resection 61 glioma tumors 61 fluorouracil 61 lymphovascular invasion 61 KRAS wild 61 Hepatocellular Carcinoma HCC 61 tumor regressions 61 AGTR1 61 radioiodine therapy 61 pleomorphic 61 colorectal pancreatic 61 alveolar epithelial cells 61 TRAIL R1 61 neoadjuvant 61 adenocarcinoma 61 achieved ACR# 61 aminotransferases 61 inhibited tumor 61 ductal cancer 61 neuroblastoma tumors 61 EUS FNA 61 hypophosphatemia 61 allogeneic HSCT 61 arteriography 61 carcinoembryonic antigen 61 mononuclear cells 61 uveal melanoma 61 thrombotic complications 61 urothelial carcinoma 61 metastatic malignant melanoma 61 FLT3 ITD 61 HER2 positive cancers 61 pT2 61 fluvastatin 61 pathologic examination 61 MALT lymphoma 61 intra arterial 61 imetelstat 61 malignant prostate 61 localized renal 61 evaluable subjects 61 invasive carcinoma 61 fibrinolysis 61 PASI scores 61 F FDG PET 61 undergoing coronary artery 61 FOLFOX6 61 caspofungin 61 demonstrated antitumor activity 61 metaplasia 61 urothelium 61 cervical lymph node 61 opacification 61 reintervention 61 paclitaxel cisplatin 61 basal cell cancers 61 #F FDG PET 61 meningiomas 61 inflammatory lesions 61 intraperitoneal chemotherapy 61 EpCAM 61 unresectable stage 61 EBRT 61 HNSCC 61 histologic findings 61 pheochromocytoma 61 scintigraphic 61 nanomolar 61 ADPKD 61 recurrent metastatic 61 esophageal squamous cell carcinoma 61 leukemic cell 61 BRCA1 mutation carriers 61 nonmelanoma skin cancers 61 HbF 61 immunostaining 61 ductal lobular 61 colorectal neoplasms 61 allogeneic transplant 61 bortezomib 61 carcinoids 61 μg ml 61 Radiofrequency ablation 61 renal pelvis 61 dosage regimens 61 Histological examination 61 radiolabeled antibodies 61 papillary RCC 61 cardiac dysfunction 61 lesions 61 lactate dehydrogenase 61 endostatin 61 peripheral blood mononuclear 61 refractory AML 61 dacarbazine DTIC 60 FluCAM arm 60 renal parenchyma 60 hepatic resection 60 core needle biopsy 60 curative resection 60 explants 60 thyroid nodules 60 rFVIIa 60 medullary thyroid cancer 60 T2DM 60 subretinal 60 prostate TURP 60 sentinel nodes 60 occult metastases 60 sleeve lobectomy 60 parathyroid 60 radiofrequency ablation RFA 60 invasive ductal 60 distal colon cancer 60 radiotherapy RT 60 papillomas 60 autoantibody positive 60 HER2 overexpression 60 Folfox 60 resections 60 interferon ribavirin 60 pancreatic cancers 60 cytokeratin 60 SSc 60 nephrotoxicity 60 clinically detectable 60 carcinoma 60 conventional angiography 60 transthoracic 60 xenografts 60 MabCampath 60 progression TTP 60 biliary strictures 60 intraocular inflammation 60 Glioblastoma Multiforme GBM 60 liposomal doxorubicin 60 Radical prostatectomy 60 pituitary adenomas 60 axillary node 60 achieved CCyR 60 neoplasm 60 gastrointestinal stromal tumors GIST 60 ischemic cardiomyopathy 60 tumorigenicity 60 NOD SCID mice 60 medically inoperable 60 LHRH receptor positive 60 pericardial effusion 60 splenic 60 Study GL# 60 leucopenia 60 axillary node dissection 60 isolated systolic hypertension 60 Subgroup analysis 60 pan HDAC inhibitor 60 lymph node metastasis 60 irinotecan chemotherapy 60 lymphopenia 60 ventricular myocardium 60 Figure 2C 60 EGFR mutation positive 60 mesangial 60 lung resection 60 antiangiogenic therapy 60 vinorelbine 60 androgen independent 60 transarterial 60 plasma pharmacokinetics 60 milatuzumab 60 histologically proven 60 edifoligide 60 TKAs 60 HER2 expression 60 cytologically confirmed 60 azacitidine 60 choroidal neovascularization CNV 60 trans retinoic acid ATRA 60 pT3 60 tumor histology 60 incisional 60 primary patency 60 imatinib Gleevec 60 μmol L 60 total thyroidectomy 60 thrombocytopenic 60 malignant lymphoma 60 immunoreactivity 60 symptomatic VTE 60 PSMA ADC 60 ALA PDT 60 HER2 positive metastatic breast 60 cerebral angiography 60 bronchoalveolar lavage 60 mammary tumors 60 TTF Therapy 60 recanalization 60 subependymal giant cell 60 plus gemcitabine 60 radical prostatectomy RP 60 ablative therapy 60 gastric cancers 60 pulmonary artery banding 60 receiving VICTRELIS 60 low expressors 60 oral clodronate 60 neurofibromas 60 paragangliomas 60 ductal 60 FDG-PET/CT 60 severe neutropenia 60 leiomyosarcoma 60 oral allopurinol 60 acute aortic dissection 60 cutaneous melanoma 60 busulfan 60 fibrinolytic therapy 60 sentinel lymph node biopsy 60 ejection fractions 60 tenecteplase 60 idarubicin 60 subcutaneous tissue 60 KRAS mutations 60 virologic breakthrough 60 IDH1 mutation 60 renal carcinoma 60 axillary lymph node dissection 60 CC genotype 60 TNFa 60 LV dysfunction 60 portal vein thrombosis 60 Histopathologic examination 60 mediastinum 60 fibrotic disease 60 timepoints 60 EGFr 60 flutamide 60 immunohistochemical 60 pleurodesis 60 carcinoid 60 lymphadenectomy 60 lymphoid cells 60 imipenem 60 pelvic lymphadenectomy 60 visceral metastases 60 catheter angiography 60 mdx mice 60 FDG PET 60 neoplasms 60 endocrine therapies 60 APTIVUS r 60 lung fibrosis 60 BRAF V#E mutation 60 carboplatin paclitaxel 60 allogeneic stem cell 60 metastatic malignant 60 carcinomatosis 60 multiple myeloma MM 60 glioblastoma multiforme GBM 60 percutaneous biopsy 60 subconjunctival injection 60 mutated KRAS gene 60 astrocytomas 60 necrotic core 60 mcg BID 60 histological subtype 60 urothelial 60 β blockers 60 pleural fluid 60 epithelial ovarian cancer 60 undetectable HBV DNA 60 submandibular gland 60 ablated 60 bypass grafting 60 transgene expression 60 hepatocellular carcinoma 60 intratumoral 60 CR CRu 60 EGFR mutations 60 prior chemotherapy regimens 60 systemically administered 60 monocytic 60 ALB # 60 salpingo oophorectomy 60 chemotherapy cisplatin 60 tumor xenografts 60 jejunal 60 isoproterenol 60 lumbar disc herniation 60 definite stent thrombosis 60 tumors GIST 60 conventional coronary angiography 60 evaluable 60 refractory NSCLC 60 clodronate 60 lymph node dissection 60 hamartoma 60 Fludara 60 paclitaxel eluting stents 60 mitral stenosis 60 parenchymal 60 VFEND 60 huN# DM1 60 arterial occlusion 60 T2 lesions 60 hormone receptor negative 60 clinically localized prostate 59 HBeAg negative patients 59 esophageal tumors 59 myelofibrosis MF 59 sulfasalazine 59 SLNB 59 oral squamous cell 59 NovoTTF 59 thyroglobulin 59 allogeneic transplants 59 computed tomographic scan 59 esophageal gastric 59 mononuclear 59 vWF 59 cholangiocarcinoma 59 recurrent glioblastoma multiforme GBM 59 CYPHER Stent 59 4mg/kg 59 #.#ng/ml 59 Circulating tumor cells 59 Seliciclib 59 recurrent glioblastoma 59 carotid artery thickness 59 IGFBP 3 59 Surgical resection 59 zotarolimus 59 graft occlusion 59 MACCE 59 micafungin 59 colonic mucosa 59 pain palliation 59 familial ALS 59 VELCADE melphalan 59 idraparinux 59 pDC 59 submucosal 59 BCG refractory 59 contralateral 59 HBeAg negative 59 hyperplastic 59 chemotherapeutic regimens 59 serum urate levels 59 hemoglobin A1c levels 59 neoplasias 59 pancreatic NET 59 8mg/kg 59 pancreatic lung 59 Hurthle cell 59 mutant p# 59 thromboembolic events 59 chemoresistant 59 CIMZIA TM 59 Amrubicin 59 Xanafide 59 chronic GVHD 59 haematopoietic 59 lymphatic tissue 59 ductal carcinomas 59 total abdominal hysterectomy 59 5-FU/LV 59 GnRH agonists 59 hepatocellular cancer 59 allogeneic bone marrow 59 T#I [002] 59 gastrointestinal stromal tumors 59 pouchitis 59 gadolinium enhancing lesions 59 Gliadel Wafer 59 geographic atrophy 59 Fas ligand 59 revascularization procedures 59 chemo resistant 59 WT1 59 MGUS 59 pancreatic endocrine 59 pelvic lymph nodes 59 intraperitoneal 59 cinacalcet 59 radiologically 59 xenograft tumors 59 systolic function 59 Zevalin consolidation 59 microbleeds 59 hyperalgesia 59 chest radiographs 59 GSTP1 59 postintervention 59 fluoroscopy guided 59 microdissected 59 hepatic arterial 59 non metastatic osteosarcoma 59 T2 weighted MRI 59 CTEPH 59 postoperative complication 59 NSTE ACS 59 thyroid carcinomas 59 plus dexamethasone 59 ACTEMRA TM 59 interferon beta therapy 59 keloid scarring 59 pyeloplasty 59 mRNA expression 59 oral Hycamtin 59 SGS# 59 histologic subtypes 59 DSAEK 59 PEGPH# 59 bicalutamide 59 LVEF 59 reinfarction 59 nadolol 59 radiation therapy SBRT 59 interleukin IL -# 59 trabecular bone 59 seminomas 59 squamous cell lung cancer 59 recurrent VTE 59 renal cysts 59 esophagectomy 59 serum phosphate 59 postoperative complications 59 everolimus eluting stents 59 malignant polyps 59 urine cytology 59 PsA 59 imatinib therapy 59 epithelioid 59 situ CIS 59 myeloproliferative disorder 59 sorafenib tablets 59 VEGF induced 59 transfusion syndrome 59 adjuvant therapies 59 bronchogenic carcinoma 59 gemcitabine 59 ERK1 2 59 castrate resistant 59 normothermic 59 RRM1 59 TOP2A 59 abdominal computed tomography 59 genotypic resistance 59 FOLFIRINOX 59 seropositive patients 59 myocardial reperfusion 59 neurologic progression 59 pathologic diagnosis 59 CLL SLL 59 dosing cohort 59 FOLPI 59 lipomas 59 pancreatic ductal 59 histologic subtype 59 somatostatin receptors 59 macroalbuminuria 59 Cytoxan 59 underwent liver transplantation 59 NSCLC 59 fibroma 59 severe mitral regurgitation 59 stage IIIB IV 59 sunitinib Sutent 59 full thickness plication 59 Gy fractions 59 Naive Patients 59 cediranib 59 surgical excision 59 choroidal neovascularization 59 papillary 59 basal cell carcinomas 59 BCR ABL mutations 59 cyclophosphamide chemotherapy 59 adrenocortical cancer 59 GORE TAG Device 59 MitraClip device 59 nephrectomies 59 iNOS 59 penetrating keratoplasty 59 plus methotrexate 59 tNOX 59 inducible nitric oxide synthase 59 CANCIDAS 59 retrospective cohort 59 SCCHN 59 HER2 receptor 59 severe exacerbations 59 neovascularization 59 glycoprotein IIb IIIa inhibitors 59 extrapleural pneumonectomy 59 histopathological 59 trastuzumab Herceptin R 59 endoscopic resection 59 advanced neoplasia 59 mitoxantrone 59 elevated triglyceride levels 59 squamous 59 ER CHOP 59 pediatric acute lymphoblastic 59 enhanced sonography 59 esophagogastric 59 prostate cancer mCRPC 59 colon tumors 59 receptor tyrosine kinase inhibitor 59 circulating EPCs 59 mcg kg REBETOL 59 pleural mesothelioma 59 NSCLC tumors 59 mitoxantrone plus 59 FluCAM 59 neuroblastomas 59 transaminase levels 59 biopsy specimens 59 free survival PFS 59 docetaxel Taxotere ® 59 cerebrospinal fluid CSF 59 IFN α 59 pretransplant 59 Akt phosphorylation 59 Postoperatively 59 Flu Cy 59 parotid 59 serum urate 59 H. pylori eradication 59 enucleation 59 adenomyosis 59 needle aspiration 59 rhBMP 2 59 lenalidomide Revlimid R 59 teriflunomide 59 FDG PET imaging 59 carotid stenosis 59 polypoid 59 #Gy 59 bronchoalveolar lavage BAL 59 neointimal 59 intraventricular 59 sarcomas 59 malignant ascites 59 eribulin 59 MLL AF9 59 carotid plaque 59 elacytarabine 59 ACR# responses 59 solid tumors 59 iodixanol 59 PRADAXA #mg 59 tumor biopsies 59 CHOP chemotherapy 59 homozygotes 59 advanced epithelial ovarian 59 posterior fossa 59 extramedullary 59 CMV disease 59 standard chemotherapy regimen 59 cytogenetic response 59 hyperoxaluria 59 carcinoid tumors 59 IFN alfa 59 lymphadenopathy 59 VAPRISOL 59 mapatumumab 59 non squamous 59 sorafenib Nexavar 59 IL 1ß 59 RF ablation 58 cystoscopic 58 electrical cardioversion 58 Immunohistochemical staining 58 microvessel density 58 brain parenchyma 58 hyperemia 58 nonsquamous 58 nonresponders 58 primary immunodeficiency PI 58 infarcted 58 orthotopic model 58 antitumor activity 58 liposarcoma 58 FUSILEV enhances 58 c MYC 58 autologous transplantation 58 neuroendocrine cancers 58 underarm lymph nodes 58 GPNMB 58 BARACLUDE ® 58 transesophageal echocardiography 58 TET2 58 elevated serum creatinine 58 hypercalcemia 58 thyroid nodule 58 BRCA deficient 58 precancerous polyp 58 metastatic bone 58 hilar 58 MAGE A3 58 carcinoma HCC 58 HBeAg positive patients 58 malignant nodules 58 CA4P 58 papillary thyroid carcinoma 58 oncologic outcomes 58 metastatic prostate 58 BRAF mutations 58 leukemic cells 58 histologic 58 doxorubicin cyclophosphamide 58 osteoid 58 rt PA 58 galiximab 58 anti leukemic 58 nonalcoholic steatohepatitis NASH 58 bladder carcinoma 58 Helicobacter infection 58 intracoronary 58 intravenous diuretics 58 radiographic findings 58 cell lymphoma CTCL 58 Toxicities 58 LHRH agonists 58 bendamustine 58 myoma 58 hematologic toxicity 58 reimplantation 58 low dose cytarabine